PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 2112570
PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 2112570
The global companion animal diagnostics market was valued at USD 2.9 billion in 2025 and is projected to reach USD 6.0 billion by 2032, growing at a CAGR of 11.0% between 2026 and 2032. Growth is being driven by rising pet adoption and the trend of pet parenting, as approximately 95 million U.S. households owned at least one pet in 2025, according to the American Pet Products Association.
Longer companion animal lifespans are reinforcing demand. Pets are living longer, healthier lives than a decade before, according to the Federation of European Companion Animal Veterinary Associations, increasing risks of liver disease, cancer, and joint disease that require diagnostic monitoring.
Advanced technologies including AI and portable point-of-care instruments are improving veterinary diagnostic capabilities, as the World Organisation for Animal Health's international standards support stronger veterinary healthcare systems and wider diagnostic adoption.
Key Insights
Immunodiagnostics hold the largest technology share, at 40%, given high sensitivity and rapid turnaround times preferred by veterinary practitioners. Molecular Diagnostics post the highest CAGR, at approximately 11.5%, driven by increasing adoption of PCR-based assays and multiplex panels.
Dogs hold the larger animal-type share, at 75%; the U.S. dog population reached 87.3 million in 2025, present in 42.6% of U.S. households, according to the AVMA's 2025 Pet Ownership and Demographics Sourcebook. Cats post the higher CAGR, at approximately 11.3%, as the U.S. cat population increased from 73.8 million in 2024 to 76.3 million in 2025.
Clinical Pathology is the largest application at 45% share, forming the backbone of routine diagnostic workups; a 2024 IDEXX Laboratories study analyzing wellness results from 167,593 dogs and 54,211 cats confirmed routine testing frequently identified clinically relevant abnormalities. Virology posts the highest CAGR, at approximately 11.7%, driven by rising viral disease prevalence and point-of-care diagnostics.
North America holds the largest regional share, at 40%, driven by growing pet populations and surging pet insurance penetration. The U.S. pet industry generated approximately USD 158 billion in expenditure in 2025, according to the APPA, with veterinary care and diagnostics spending continuing to rise.
Asia-Pacific posts the highest regional CAGR, at approximately 11.9%, driven by rising zoonotic disease prevalence and growing animal health awareness alongside surging incomes and urbanization.
Molecular and AI-enabled testing platforms are a defining trend, as cartridge-based PCR systems complement traditional reference laboratory workflows. India's ICAR-NIVEDI uses AI and machine learning through its NADRES V2 platform to provide monthly disease risk forewarnings for 15 economically important animal diseases.
Zoonotic disease surveillance and preventive care remain the biggest driver. 74.2% of U.S. dog owners and 57.3% of cat owners reported visiting a veterinarian in 2024, according to the American Veterinary Medical Association, reflecting sustained demand for preventive care.
Veterinary workforce shortages are the main restraint, as smaller and rural practices often lack the technical expertise and patient volumes needed to justify investment in molecular diagnostic systems and point-of-care analyzers.
Increasing pet insurance adoption presents a clear opportunity. 7.03 million pets were insured in North America at the end of 2024, a 12.2% increase from 2023, according to the North American Pet Health Insurance Association, generating USD 5.2 billion in written premiums.
The competitive landscape features established veterinary diagnostics providers competing on molecular and immunoassay innovation. Recent activity includes IDEXX Laboratories' expansion of its Fecal Dx antigen testing platform in May 2026 to include taeniid tapeworm species detection, and IDEXX's January 2025 launch of the Cancer Dx panel, a blood-based screening test for early detection of canine lymphoma during routine wellness examinations.